Abiopharma

🔍 KENNEY CHRISTOPHER JOHN (Executive)

Company: Xenon Pharmaceuticals Inc. (XENE)

Report Date: 2026-03-12

Detailed Transactions and Holdings:

• Acquired 3,750 shares of Common Shares (Direct)
  Date: 2026-03-12 | Code: M | equity_swap_involved: false | shares_owned_after: 8,479.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 1,410 shares of Common Shares at $55.225 per share (Direct)
  Date: 2026-03-13 | Code: S | equity_swap_involved: false | shares_owned_after: 7,069.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 3,750 shares of Restricted Share Units (Derivative)
  Date: 2026-03-12 | Code: M | equity_swap_involved: false | shares_owned_after: 11,250.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1

Footnotes:

• F1: Represents shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026.
• F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading arrangement, in the form of a durable sell-to-cover instruction, adopted by the reporting person on December 3, 2025, solely to satisfy tax withholding obligations related to the vesting of RSUs granted on March 12, 2025.